2 DiviDog Buys By Barron's Mid-Year Round Table Pros

Barron's Mid-Year 2026 Roundtable highlights 45 Pro Picks, with yield-based 'dogcatcher' analysis identifying top dividend opportunities. PetroChina and BP emerge as the two 'safer' ideal dividend dogs, with prices below the annual dividend payout from $1K invested. Top ten yield stocks, including SAP, BP, and Exxon Mobil, are projected to deliver 13.85%–61.68% gains by July 2027, with an average net gain of 24.48%.

Seeking Alpha • Jul 17, 2026

Artisan Mid Cap Fund Q2 2026 Performance Review

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.

Seeking Alpha • Jul 15, 2026

Carillon Eagle Mid Cap Growth Fund Q2 2026 Portfolio Review

Carillon Eagle Mid Cap Growth Fund stocks delivered solid results in the second quarter. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions.

Seeking Alpha • Jul 14, 2026

Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2026 on Wednesday, August 5, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 5, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer Eva C. Boratto, Executive Vice President & Chief.

Business Wire • Jul 1, 2026

Costco, Exxon, and 17 More Winners if the Market Drops

These stocks can hold their ground, or even gain, when the market falls. And a garden variety correction—a 10% drop or more—is quite possible.

Barrons • Jun 24, 2026

Cencora Launches Enhanced Nucleus Solution for Specialty Practices

COR's enhanced Nucleus platform targets complex specialty medication workflows, with a pilot underway across more than 20 physician practice sites.

Zacks Investment Research • Jun 18, 2026

COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell?

COR shares are down 18% YTD, but rising EPS guidance, specialty pharma growth and strategic expansion could make this pullback worth watching.

Zacks Investment Research • Jun 18, 2026

Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns

Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.

Zacks Investment Research • Jun 18, 2026

Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced a multi-site pilot of its enhanced Nucleus® inventory management solution, designed to help specialty physician practices manage increasingly complex medication workflows with greater efficiency, visibility and control. Developed with input from customer advisory boards and specialty care providers, the updated platform combines redesigned physical infrastructure with software and interface e.

Business Wire • Jun 17, 2026

Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns

The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. TPR, VRT, CLS and COR are some such stocks.

Zacks Investment Research • Jun 17, 2026